On May 8, 2020, Beijing Scitech-MQ Pharmaceutical Limited (Scitech Pharma)filed application for its investigational new drug ST-1898, which has been officially accepted by the Center for Drug Evaluation of National Medical Products Administration (acceptance number: CXHL2000207/CXHL2000208). ST-1898 is a novel small molecule inhibitor whose global intellectual property rights are solely owned by Scitech Pharma.

ST-1898 was discovered and developed by Scitech Pharma. It is a multi-target tyrosine kinase inhibitor intended to be used for the treatment of solid tumors. Preclinical results indicate that ST-1898 can significantly inhibit the tumor growth in multiple mice xenograft models (including CDX/PDX models of liver cancer, lung cancer, gastric cancer, colon cancer etc.). ST-1898 can effectively inhibit many different tyrosine kinases known to be closely related to the occurrence and the growth of tumors. As a result, it has the potential to be used for many different indications. It is expected to provide a new treatment option for cancer patients around the world and to benefit human health.

来源：